Keyphrases
Melanoma
63%
Metastatic Melanoma
55%
Tumor-infiltrating Lymphocytes
37%
Pembrolizumab
32%
Advanced Melanoma
29%
Melanoma Patients
25%
Ipilimumab
24%
Adoptive Cell Therapy
21%
Melanoma Cells
16%
Phase II Trial
15%
Malignant Melanoma
15%
Overall Survival
15%
Dabrafenib Plus Trametinib
12%
CEACAM1
11%
Vemurafenib
11%
Progression-free Survival
11%
Stage III Melanoma
11%
Placebo
10%
T Cells
10%
Chimeric Antigen Receptor T Cells (CAR-T)
9%
Phase II Study
9%
Confidence Interval
9%
BRAF V600E
9%
Interferon-α (IFN-α)
9%
Hazard Ratio
8%
Dabrafenib
8%
Combination Therapy
8%
BRAF Inhibitor (BRAFi)
8%
Trametinib
8%
Tumor
8%
Immune-related Adverse Events
8%
Adoptive Cell Transfer
8%
Adverse Events
8%
Adjuvant Therapy
8%
Chemotherapy
8%
BRAF V600E mutation
7%
Disease Progression
7%
Nivolumab
7%
Immune Checkpoint Inhibitors
7%
Interleukin-2
7%
Health-related Quality of Life
7%
Metastatic Cutaneous Squamous Cell Carcinoma
7%
Cell Adhesion Molecule 1 (CADM1)
7%
Monotherapy
6%
Response Rate
6%
Complete Response
6%
Cancer Treatment
6%
Antitumor Activity
6%
MicroRNA
6%
Sentinel Lymph Node
6%
Medicine and Dentistry
Nodular Melanoma
100%
Metastatic Melanoma
35%
Neoplasm
25%
Pembrolizumab
24%
Tumor Infiltrating Lymphocyte
23%
Immunotherapy
22%
Disease
18%
Cell Therapy
16%
Ipilimumab
15%
Overall Survival
14%
T Cell
13%
Dabrafenib
11%
Placebo
11%
Trametinib
11%
Progression Free Survival
11%
Adverse Event
11%
Carcinoembryonic Antigen Related Cell Adhesion Molecule 1
10%
Immune Checkpoint Inhibitor
8%
Malignant Neoplasm
8%
Interleukin 2
8%
Metastatic Carcinoma
8%
Sentinel Node
8%
Melanoma Cell
8%
Quality of Life
7%
Hazard Ratio
7%
Interferon
7%
Adjuvant Therapy
7%
Drug Megadose
6%
Chimeric Antigen Receptor T-Cell
6%
Surgery
6%
Transfer Cell
5%
Retroperitoneal Lymph Node Dissection
5%
Prognostic Factor
5%
Adoptive Transfer
5%
Arm
5%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
63%
Metastatic Melanoma
37%
Neoplasm
29%
Pembrolizumab
23%
Overall Survival
21%
Ipilimumab
19%
Adverse Event
17%
Immunotherapy
17%
Trametinib
15%
Dabrafenib
15%
Progression Free Survival
14%
Vemurafenib
11%
Malignant Neoplasm
10%
Disease
10%
Chemotherapy
10%
Placebo
9%
Combination Therapy
8%
Interferon
6%
Skin Carcinoma
6%
Monotherapy
5%
Nivolumab
5%
Lactate Dehydrogenase
5%